Clinical Trials Logo
  1. Home
  2. Cancer of the Head and Neck
  3. NCT01370876

Efficacy and Safety Study of Oxaliplatin/5-FU in Patients With Recurrent or Metastatic Head and Neck Cancer

Cancer of the Head and Neck Clinical Trial

Official title:
A Phase II Trial Evaluating Efficacy and Safety of Opatin® (Oxaliplatin)/5-FU in Patients With Recurrent or Metastatic Head and Neck Cancer

Clinical Trial Summary

To evaluate the objective response rate of oxaliplatin combined with 5-FU in patients with recurrent or metastatic head and neck cancer and to assess the safety profile of these treatment regimen.

Clinical Trial Description

To evaluate the objective response rate of oxaliplatin combined with 5-FU in patients with recurrent or metastatic head and neck cancer.

To assess the safety profile of these treatment regimen. To evaluate the duration of response of oxaliplatin/5-FU. ;

Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT01370876
Study type Interventional
Source Nang Kuang Pharmaceutical Co., Ltd.
Contact
Status Terminated
Phase Phase 2
Start date September 2010
Completion date May 2012
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT04444869 - Testing Less Intensive Radiation With Chemotherapy to Treat Low-risk Patients With HPV-positive Oropharyngeal Cancer Phase 2
Terminated NCT03297957 - Fluorescence Imaging in Head and Neck Cancer N/A
Completed NCT00716157 - Incidence and Patterns of Nausea/Vomiting With Combined Chemotherapy and Radiation N/A
Recruiting NCT04880148 - The Effectiveness of a Thyme and Honey Spray for Oral Toxicities N/A
Completed NCT01017224 - DAHANCA 24: Prognostic Value of 18F-FAZA in Head and Neck Squamous Cell Carcinoma (HNSCC) N/A
Completed NCT00798655 - Trial of Postoperative Radiation, Cisplatin, and Panitumumab in Locally Advanced Head and Neck Cancer Phase 2
Completed NCT00496652 - DAHANCA 19: The Importance of the EGFr-inhibitor Zalutumumab for the Outcome After Curative Radiotherapy for HNSCC Phase 3
Recruiting NCT03620084 - Effects of Expiratory Muscle Strength Training on Airway Protection and Swallowing in Chronic Dysphagia After Radiation Therapy N/A
Completed NCT00147472 - Positronic Emission Tomography (PET) Imaging in Post Radiation Evaluation of Head and Neck Tumours (PET PREVENT Trial) Phase 3
Completed NCT02880072 - Absorption of Orally Ingested Phosphate in Refeeding Syndrome Phase 4
Completed NCT01917942 - Radiotherapy With Humidification in Head And Neck Cancer Phase 3
Recruiting NCT04865731 - Dermaprazole Cream for Radiation Dermatitis in Head and Neck Cancer Phase 2
Completed NCT02442336 - A Web-Based Multimedia Intervention for Head and Neck Cancer Patients N/A
Completed NCT03102229 - Real-time Activity Monitoring to Prevent Admissions During RadioTherapy N/A
Completed NCT00474825 - Dose Escalation Study of Hyperbaric Oxygen With Radiation and Chemotherapy to Treat Squamous Cell Carcinoma of the Head and Neck Phase 1
Recruiting NCT00180921 - Study of Imatinib (Glivec) in Patients With Adenoid Cystic Carcinoma of the Head and Neck Phase 2
Completed NCT01283334 - A Study of Carboplatin, Cetuximab and RAD001 in Advanced Head and Neck Cancer Phase 1/Phase 2
Recruiting NCT02557048 - Head and Neck Cancer in Children: A Retrospective Study
Completed NCT02073032 - Incidence and Risk Factors of Refeeding Syndrome N/A
Active, not recruiting NCT02270814 - Cisplatin, Nab-Paclitaxel, and Cetuximab (CACTUX) in Patients With Incurable Head and Neck Squamous Cell Carcinoma Phase 2